Medpace Holdings Inc vs Navitas Semiconductor Corporation Common Stock — how do they compare? Medpace Holdings Inc trades at $602 (market cap $16.82B), while Navitas Semiconductor Corporation Common Stock trades at $11.29 (market cap $2.87B). The key difference: Medpace Holdings Inc is far larger — about 5.9× Navitas Semiconductor Corporation Common Stock's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Navitas Semiconductor Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Navitas Semiconductor Corporation Common Stock for 0 Days on average.
| MEDP | NVTS | |
|---|---|---|
Market Cap | $16.82B | $2.87B |
Volume | 223,093 | 13,752,519 |
Sector | Health | Technology |
52-Week High | $630.19 | $31.79 |
52-Week Low | $393.42 | $7.14 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $16.44B | $2.32B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% with neutral technical signals and strong fundamental performance. The stock shows robust profitability with 17.67% net income margin and consistent earnings beats in recent quarters. Recent news highlights institutional activity including CEO stock sales and upcoming Q3 2026 earnings report on October 21, 2026. Technical indicators show mixed signals with RSI neutral and ADX bullish, while support sits at $589 and resistance at $629.
MEDP presents a mixed outlook with strong fundamentals offset by high valuations and insider selling. The 21% buy rating from analysts suggests cautious optimism, with $620.44 price target offering 2.7% upside. Key risks include elevated P/E ratio of 35.5 and recent CEO stock sales totaling over $44 million in September 2026. Positive cash flow projection for 2026 supports growth potential despite current net outflow.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Navitas Semiconductor designs and markets gallium nitride and silicon carbide power semiconductors. Its products are used in power conversion and charging for data centers, energy infrastructure, and industrial applications.
Read more on NVTS →